^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
NMS-153
i
Other names: NMS-153, NMS-01940153E
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Nerviano Medical Sciences
Drug class:
TTK inhibitor
Related drugs:
3ms
Study on Safety and Efficacy of NMS-01940153E in Adult Patients With Unresectable Hepatocellular Carcinoma (HCC) Previously Treated With Systemic Therapy (clinicaltrials.gov)
P1/2, N=31, Active, not recruiting, Nerviano Medical Sciences | Recruiting --> Active, not recruiting | N=57 --> 31 | Trial completion date: Mar 2026 --> Mar 2025 | Trial primary completion date: Nov 2025 --> Jan 2024
Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
|
NMS-153
11ms
Study on Safety and Efficacy of NMS-01940153E in Adult Patients With Unresectable Hepatocellular Carcinoma (HCC) Previously Treated With Systemic Therapy (clinicaltrials.gov)
P1/2, N=57, Recruiting, Nerviano Medical Sciences | Trial completion date: Mar 2027 --> Mar 2026 | Trial primary completion date: Nov 2026 --> Nov 2025
Trial completion date • Trial primary completion date
|
NMS-153
Share via
